Organization | Fondazione del Piemonte per l'Oncologia

Fondazione del Piemonte per l'Oncologia Report issue

Foundation Phase 2

Founded: Candiolo Italy

Organization Overview

First Clinical Trial

2010

NCT01389414

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Fondazione del Piemonte per l'Oncologia | Prof. Massimo Aglietta

Active Ingredients

Drugs in Phase 2 Trials (9)

carboplatin (paraplatin) (1 trial)

gemcitabine (gemzar) (2 trials)

lapatinib (tykerb) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

panitumumab (vectibix) (2 trials)

pertuzumab (perjeta) (1 trial)

trastuzumab (herceptin) (1 trial)

trastuzumab emtansine (kadcyla) (2 trials)

Drugs in Other Trials (3)

inulin (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Neoplasms, Unknown Primary (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 12